The acquisition of Aciex follows the recent expansion of Nicox's commercial presence for its ophthalmic diagnostics franchise in the US to support its recently launched products, including Sjö(TM) for the early detection of Sjögren's syndrome in patients with dry eye symptoms, and RetnaGene(TM) for comprehensive risk assessment for advanced age-related macular degeneration (AMD). The US team also promotes AdenoPlus ®, launched in late 2012, a point-of-care test to aid in the differential diagnosis of acute conjunctivitis. Two other diagnostic tests, one targeting both adenoviral and allergic conjunctivitis and the other targeting ocular herpes, are in development. In Europe, Nicox markets Xailin(TM), a proprietary brand of tear lubricants for relief of dry eye symptoms, and AdenoPlus ®. An additional range of products is also marketed in Italy through the Group's subsidiary Eupharmed, acquired at the end of 2013.